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ABSTRACT 
 
The successful delivery of vaccine antigens such as peptides and proteins to 
stimulate CD4 and CD8 T cell immunity could provide a prevention or treatment of 
infectious diseases and malignant disorders.  This project tested different strategies 
of peptide delivery to phagocytic cells using β-glucan particles (GPs), and assayed 
the in vitro immune-stimulatory capabilities.  GPs are hollow microparticles derived 
from Baker’s yeast that can be used to encapsulate or bind peptide payloads to 
ensure delivery to target cells. Various synthetic strategies were evaluated to 
identify an effective delivery method for in vitro testing using a T-cell proliferation 
assay. 
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BACKGROUND 
 
Role of Vaccines in Human Health 
Significant progress has been made over the past several years in the areas of 
virology, immunology, and the development of vaccines. Vaccines have been a 
critical part of the fight against various diseases both in the developed and the 
developing world. The introduction of vaccines into medical practice has had an 
outstanding impact on human health, drastically diminishing or eradicating the 
incidence and morbidity of a large number of infectious diseases such as smallpox, 
polio, and diphtheria.  Currently, three main types of vaccines are used in humans: 
live-attenuated vaccines composed of a virus or bacterium that is less pathogenic 
than the real pathogen, inactivated vaccines that are heat- or chemically-inactivated 
particles of the pathogen, or subunit vaccines that are made of components of the 
pathogen.  In the process of attenuation, an infectious agent is altered so that is less 
virulent, while retaining its ability to interact with the host organism and stimulate 
an immune response (Badgett et al., 2002).  Live attenuated vaccines are often able 
to induce strong, long-lasting immunity. An example of successful live attenuated 
vaccines that are delivered by injection is a vaccine for measles, mumps, rubella and 
the varicella zoster virus (Knuf et al., 2008). There are also a number of mucosally 
delivered live vaccines, including oral vaccines against poliomyelitis (Bonnett and 
Dutta, 2008), cholera, and typhoid fever (Levine, 2000). Live attenuated vaccines 
have a number of advantages over the others, such as the effective stimulation of 
cellular, humoral, and mucosal immunity, and their low cost.  Despite these 
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advantages, there are some downsides including storage limitations and possible 
mutations of the organism, which often leads to negative effects.  For cases in which 
live attenuated vaccines have serious adverse effects, further refinement of the 
vaccine can sometimes be provided by developing an inactivated formulation for 
immunization by killing the disease-causing agent with chemicals, heat or radiation. 
Most inactivated vaccines, however, stimulate a weaker immune response than do 
attenuated vaccines. The comparison study on live attenuated versus inactivated 
influenza vaccines showed that the live vaccines are more efficient and safer, when 
administered to infants and young children of 12 to 59 months of age (Belshe et al., 
2007). In contrast, a live attenuated oral cholera vaccine showed no significant 
protection in a large field trial in Indonesia. These results demonstrate that 
inactivated vaccines can elicit some degree of immunity and provide protection 
from mucosal pathogens (Richie et al., 2000).  
Recent advances in molecular biology and genetics gave rise to the ability to 
produce subunit vaccines.  Subunit vaccines include only the antigens that best 
stimulate the immune system, lessening the chance of adverse reactions to the 
vaccine. The first recombinant subunit vaccine against Hepatitis B was developed in 
1986 in Saccharomyces cerevisiae by isolating and transferring the gene encoding 
the Hepatitis B surface antigen into a non-pathogenic organism (yeast). The 
recombinant subunit vaccine was then produced by the yeast, and could be purified 
for vaccine purposes and designed for delivery (Valenzuela et al., 1982).  Today, 
recombinant subunit vaccines are being investigated in the development of new 
vaccines or more effective vaccines with less adverse effects. 
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The Immune System 
The immune system of multicellular organisms plays an essential role in 
protecting the host against infection, and consists of two components: innate and 
adaptive immunity. Innate immunity is triggered by infection to protect the host 
organism by destroying the invading microbes and viruses, while adaptive 
immunity develops with exposure to various antigens, building a defense that is 
specific to that antigen.  
 
Innate Immunity 
Innate immunity is the first-line of the host-defense, and is mediated by 
leukocytes, macrophages and dendritic cells, which engulf and kill the microbes. 
Initially, the innate immune system response was thought to be non-specific, relying 
on a very limited number of receptors that recognize the structure of microbes.  
However, a study done in Drosophila showed that protein Toll was critical for 
defending fruit flies against fungal infections (Lemaitre et al., 1996), and this led to 
the identification of at least 10 similar proteins, named toll-like receptors (TLRs) 
that recognize and respond to infection by enabling innate response and also 
inducing an adaptive response  (Takeda et al., 2003).  Pathogens are “betrayed” to 
the innate immune system by pathogen-associated molecular patterns (PAMPs) that 
are vital for their own homeostasis (Janeway, 1989). Innnate immune cells can 
recognize PAMPs through TLRs expressed on the cell surface, which leads to 
activation of T cells. The innate immune system provides an immediate defence 
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against the infection, and is considered as a temporary system until adaptive 
immunity is induced (Akira, 2011).  
 
Adaptive Immunity 
In some cases, the innate immune system is unable to fight the infection, so 
the activation of an adaptive immune system is required. Adaptive immunity 
recognizes peptide antigens using antigen receptors expressed on the surface of B 
and T lymphocytes. These cells are able to rearrange their immunoglobulin and cell 
receptors genes to generate a vast variety of different antigen receptors.  Adaptive 
immunity is further divided into humoral and cellular immunity.  
Cell-mediated immunity is responsible for the eradication of intracellular 
pathogens and is driven by T lymphocytes. T cells target pathogen-infected cells 
through peptide-bound MHC class I molecules expressed on the cell surface, 
inducing apoptosis through perforin- and granzyme (granule enzyme) -mediated 
cytolysis (Lieberman, 2003).  Humoral immunity (antibody production) is involved 
in the destruction of microbes present in the blood or fluid by generating antibodies 
produced by B cells.  Antibodies bind to pathogens, blocking infection by mediating 
phagocytosis or by helping activate the complement pathways.  CD4+ helper T cells 
play a role in humoral immunity by driving B cell maturation to antibody secreting 
plasma cells (Kutteh and Mestecky, 1994).  Components of humoral immunity 
include soluble pattern recognition molecules (PRMs) that recognize PAMPs and 
initiate the immune response in coordination with cellular immunity. 
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Vaccine Development 
Subunit Vaccines 
The goal of vaccination is to generate a strong immune response, providing a 
long-term protection against infection. Many of the vaccines developed during the 
last two decades are based on the subunit approach. Different strategies of 
generating subunit vaccines were developed such as crude extracts, proteins, MAPs, 
and peptides.  
 
Multiple Antigenic Peptides (MAPs) 
The method of multimerization of peptides, known as the multiple antigenic 
peptide (MAP) system, was developed by Tam to improve the immunogenicity of 
subunit peptide vaccines (Tam, 1988). In this MAP system, multiple copies of 
antigenic peptides are simultaneously bound to Lys-based dendrimer and were 
used to induce higher amounts of antibody production. However, additional 
components such as adjuvants were required to achieve the effects.  In a study done 
by Kumar, multiple T-cell and B-cell epitopes from Plasmodium falciparum were 
synthesized as the constituents of MAP, and showed induced antibody and cellular 
responses in mice (Mahajan et al., 2010). The antibodies generated by this 
immunization significantly reduced the growth of blood stage parasites in 
erythrocyte cultures.  
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Crude Extract Vaccines 
Lopez et al. (2007) developed a strategy to generate bioactive compounds 
through the chemical diversification of inactive crude product mixtures, which gave 
rise to the development of crude extract subunit vaccines (Lopez et al., 2007).  An 
example of such vaccine is the use of Pasteurella lipoprotein E (PlpE) as a subunit 
vaccine to protect animals from diseases caused by P. multocida.  The vaccine is 
comprised of lipoprotein PlpE as an antigen and adjuvant (Chang et al., 2011). This 
chemical diversification approach provides a great potential for developing a 
practical vaccine to assist with the control of human diseases.  
 
Protein and Peptide Vaccines 
Proteins and peptides are increasingly recognized as excellent prospects for 
the development of new vaccines.  Peptides, identiﬁed as immunogenic epitopes, 
can elicit a strong immune response when delivered together with a carrier (Simard 
et al., 1997) or an adjuvant (Hsu et al., 1996). Peptide and protein therapy allows 
delivery in very low doses due to their specificity. However, various obstacles to 
their successful delivery hamper their therapeutic potential and clinical application. 
Recent studies in the fields of liposomes, microparticle, and polymer conjugation 
strategies allowed the development of novel peptide delivery systems and their 
validation in vivo.  
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Peptide Vaccine Delivery 
Microparticles 
Particles between 1 and 1000 µm are classified as microparticles. Various 
studies were done to design microparticle formulations for peptide and protein 
delivery. In a study for diabetes treatment, insulin-loaded microparticles were 
formulated for oral insulin delivery, and its effectiveness was tested through the 
reduction of initial blood glucose levels in diabetic rabbits. The blood glucose tests 
showed a 70% glucose reduction in rabbits treated with sodium alginate 
microparticles (Builders et al., 2008).  In another study, Marazuela et al. evaluated 
whether intranasal administration of synthesized peptide containing poly-(lactide-
co-glycolide) (PLGA) microparticles were able to prevent mice from allergic 
sensitivity to the whole protein. It was reported that PLGA microparticles had an 
initial burst release of 74% peptide followed by a slow release over several weeks, 
and the release decreased the allergic sensitivity (Marazuela et al., 2008). The 
studies show the effectiveness of microparticles as a potential drug delivery system. 
 
Liposomes 
Liposomes are synthetic microscopic vesicles composed of lipid membranes 
surrounding discrete aqueous compartments (Weissman and Sessa, 1968).  Due to 
their flexibility in size, composition, and charge, various types of liposome 
formulations have been developed for enzyme delivery. They have also been used 
for delivering anti-cancer drugs targeting tumor tissues (Ryman and Tyrrell, 1980).  
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However, peptides coupled to liposomes usually yield products that are chemically 
and physically ill defined. To overcome this problem, Gyongyossy-Issa et al. 
reported the use of disulfide linkages on the surface of the liposome to attach a 
peptide representing one-half of a ligand-receptor pair to achieve target specificity 
(Gyongyossy-Issa et al., 1998).  
 
Polymer Conjugation 
Renal filtration and excretion are responsible for the rapid clearance of 
serum proteins with low molecular weights from the organism.  For vaccines, this 
issue can be prevented by conjugating the biomolecules with water-soluble 
polymers, which results in molecules of higher molecular weights. Another 
advantage of peptide-polymer binding is that polymers increase the resistance 
against enzymatic degradation and lower the immunogenicity.  
Several polymers have been used for protein conjugation. Currently, poly 
(ethylene glycol) (PEG) is one of the most widely used polymers for the modification 
of peptides and proteins. This polymer is inexpensive, has low toxicity, and has been 
approved for use by drug regulatory agencies (Roberts et al., 2002).  The first Food 
and Drug Administration (FDA) approved PEGylated pharmaceutical (PEG-ADA) 
appeared in 1990 for the treatment of severe combined immunodeficiency disease 
(SCID). Since then, several more PEGylated products have received approval from 
the FDA, testifying to the safety and applicability of this polymer conjugation for the 
treatment of severe diseases (Levy et al., 1988).  Chitosan and chitosan derivatives 
have been extensively used in the delivery of therapeutic proteins due to their 
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absorption-enhancing properties. In many studies, it has been demonstrated that 
chitosan-based formulations significantly enhanced the absorption of proteins 
(Calvo et al., 1997; Vila et al., 2004). Other alternative polymers that have been 
successfully used for protein conjugation include PLL (poly-L-lysine) and PEI 
(polyethyleneimine). PLL and PEI have been widely used as non-viral vectors for 
gene delivery, favored due to the biodegradability of these polypeptides and their 
accessibility within a broad molecular weight range.  However PEI shows far 
superior delivery efficiency due to its high charge density. In the study done by 
Erbacher et al. (1999), RGD peptides were covalently bound to PEI to achieve 
specific cell adhesion enhancing cellular uptake (Erbacher et. al, 1999). Polymer 
conjugation methods can be further explored with regard to the chemistry of 
binding, as well as the development of polymers with enhanced stability, improved 
cellular uptake, and minimal adverse effects. 
 
β-Glucan Particles as an Adjuvant and Drug Delivery System 
Unlike live attenuated vaccines, both inactivated and subunit vaccines 
require the addition of an adjuvant to be effective. Adjuvants are used to enhance 
the immune response against antigens and to increase immunological memory and 
improve protection through the stimulation of immune responses. One of the key 
features of an efficient adjuvant formulation is the activation of innate immunity by 
PAMPs, which leads to protecting, long-lasting immunity against the infection. β-
glucan particles (GPs) are hollow, porous, 2-4 µm spherical particles extracted from 
Saccharomyces cerevisiae (Baker’s yeast) cell walls.  In order to prepare β-glucan 
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particles, yeast cell walls are treated so that the cell wall components and the 
soluble proteins within the yeast cell are removed (Yan et al., 2005).  GPs аre 
composed of β-1-3-D-glucan and residual chitin.  The porous and hollow structure 
of glucan particles allows encapsulation of payload molecules within the particles 
and provides the capability of delivering the drug into cells.  β-glucan cell surface 
receptors dectin-1 and Complement Receptor-3 (or CP3) allow targeted delivery of 
the drug into cells such as macrophages and dendritic cells (Brown and Gordon, 
2001).  β-glucan is considered a PAMP that acts independently of the Toll receptor 
pathways, and has been referred to as a “biological response modifier”, known for 
its ability to stimulate the immune response (Chihara, 1992). The ability of glucans 
to deliver drugs to macrophages and dendritic cells, as well as their ability to 
enhance the immune response, makes glucan particles an appealing option to 
develop formulations comprised of a peptide core inside the glucan particles as 
potential drugs.  The use of GPs for the delivery of macromolecules, such as DNA, 
siRNAs, and protein has been successfully demonstrated both in vitro and in vivo 
(Soto and Ostroff, 2008; Aouadi et al., 2009).  Different methods of trapping 
macromolecules within GPs have been tested, including polyplex formation or layer-
by-layer synthetic method, nanoparticle and GP surface derivatization. 
 
Macromolecule Loading in Cores 
The strategy of loading macromolecules in GP cores includes the physical 
entrapment of the payload drug such as Rifampicin (Rif) within the glucan particles 
using an alginate or chitosan hydrogel to slow down the release of the drug. The 
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hydrogels are high-water content materials that are prepared from cross-linked, 
biodegradable, biocompatible, and non-toxic polymers. The use of GPs for 
encapsulation of Rif was demonstrated by Ostroff and proved to delay Rif release 
from the GPs over a 24 - 72 h period (Soto et al., 2010).  
 
Macromolecule Loading in Layers 
This method entails the encapsulation of therapeutic molecules in a layer-by-
layer (LbL)-assembled GP cores.   These can accommodate high payloads, and are 
compatible with targeting and controlled release of the drug. The LbL approach 
includes the assembly of different components through electrostatic interactions. An 
efficient microparticle-encapsulated nanoplex-based DNA delivery system was 
developed by Ostroff (Soto and Ostroff, 2008). Nanoparticulate cores composed of 
anionic and cationic polymers were constructed within GPs, followed by the binding 
of DNA to it, and coated by a second cationic polymer layer to protect the DNA.  
Polyethylimine (PEI) was used as the trapping polymer layers in the original study 
to demonstrate the use of GP for DNA delivery. Currently, research is being 
conducted to find polymers with equal or better efficiency due to the cytotoxicity of 
PEI.  
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Figure 1: Schematic representation of a) a nanoparticulate core constructed 
within porous, hollow GP, and b) adsorption of DNA onto an encapsulated 
nanoparticulate core (Soto and Ostroff, 2008). 
  
Macromolecules Loading in Nanoparticles 
Nanoparticles can act as drug carriers for different water insoluble 
molecules. The development of nanomaterial for delivering such drugs has received 
significant interest in the past decade.  The ideal drug delivery system has to be able 
to target to specific cells, and to control the drug release. The ability to selectively 
target phagocytic cells makes the glucan particles a potential drug delivery system 
for nanoparticles.  
 
Loading Nanoparticles Inside GPs 
Because of the ease of synthesis and ability to entrap therapeutic drugs, 
mesoporous silica nanoparticles (MSNs) have been used as a model system to load 
nanoparticles inside the GPs.  MSNs containing the anti-cancer drug Dox 
(Doxorubicin) were electrostatically bound to GPs derivatized with PEI 
(polyethyleneimine) and were successfully delivered to the cells (Soto et al.,  2011).  
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Loading Nanoparticles Outside GPs 
In addition to the use of the hollow cavity of GPs for drug encapsulation, the 
surface of the GPs offers another option for drug binding.  Chemical derivatization of 
the GP surface has been studied to introduce targeting ligands to increase cell 
tropism of the particles, and derivatization of polymers for covalent and non-
covalent binding of payload drugs. Cationic GPs are synthesized by functionalization 
with branched PEI, and fluorescent particles of larger sizes are electrostatically 
bound to the PEI-GP surface. The studies demonstrated successful targeted delivery 
of Dox-MSN-PEI-GPs to cells inhibiting the growth of phagocytic cells (Soto et al., 
2011). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2:  Schematic depiction of several glucan 
particle/nanoparticle synthesis methods (Soto et al., 2011). 
  
Other Binding Methods 
The GP surface can also be derivatized with molecules that are used as 
universal acceptors for the attachment of ligands for specific chemical reactions. For 
instance GPs derivatized with biotin can bind ligands through biotin-avidin or 
biotin-streptavidin interactions. 
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GP Surface Modification by Derivatization with SATA 
 Another approach of GP surface modification is its derivatization with SATA 
(N-succinimidyl S-acetylthioacetate). SATA is a reagent used to introduce sulfhydryl 
groups into variety of amine-containing proteins and peptides (Duncan et al., 1983). 
SATA contains an N-hydroxysuccinimide (NHS) ester, which reacts with amine 
group by nucleophilic attack, resulting in a stable covalent bond formation.   Several 
advantages of using SATA for introducing sulfhydryl groups into proteins and 
peptides include the ease of storage, reaction with primary amines, and the addition 
of protected sulfhydryl, which is then deprotected by hydroxylamine.  
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 PROJECT PURPOSE 
 
 Vaccination is one of the most important and cost-effective methods of 
preventing infectious diseases. Previous experiments using β-glucan particles (GPs) 
have shown success in using this technology as a delivery vehicle for 
macromolecules (i.e. DNA, siRNA, and proteins), and there is an interest to extend 
its use to delivery of peptides.  The main purpose of this project was to test different 
strategies for peptide delivery using β-glucan particles. Different methods were 
tested, such as building core complexes inside the GPs, adding trapping polymers, 
GP surface derivatization with polymers, and SATA for better binding of the peptide 
to GPs.  The methods were compared for successful loading and release of the 
peptide, and for in vitro stimulation of T cell replication.  The optimum methods will 
eventually be tested for in vivo immunogenicity. 
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MATERIALS AND METHODS 
 
1. Materials 
Reagents: 
Glucan particles were prepared from Fleishmans Baker’s yeast (AB Mauri 
Food Inc, Chesterfield, MO) according to previously published procedures (Soto and 
Ostroff, 2008). C(Npys)-OVA-323-339-amide peptide (ISQAVHAAHAEINEAGR-
amide, 90.12% purity) was purchased from 21 Century Biochemicals (Marlborough, 
MA). Ovalbumin (OVA) from chicken egg white, Ribonucleic acid from torula yeast 
Type VI (tRNA), chitosan from crab shells, Poly-L-Lysine-hydrobromide (PLL), 1,3-
diaminopropane (DAP), 25 kDa branched polyethylenimine (PEI), hydroxylamine 
hydroclochloride, ethylenediamine-tetraacetic acid (EDTA), ethanol, L-glutathione 
(GSH), acetic acid and glycine were purchased from Sigma-Aldrich (Allenstown, PA), 
and used as received. Materials for cell tissue culture experiments were purchased 
from Gibco Scientific (Grand Island, NY). SATA (N-Succinimidyl S-Acetylthioacetate) 
was purchased from Pierce Chemicals (Rockford, IL). 
 
Equipment: 
The Virtis lyophilizer was from Virtis Company (Gardiner, NY), the 96-well 
Costar plates with UV transparent flat-bottom were from Corning Inc, (Corning, NY), 
the Safire Tecan microplate reader was from Tecan Group (Mannendorf, 
Switzerland). 
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2. Methods 
2.1  Preparation of GPs 
Yeast glucan particles (YGPs) were prepared from Baker’s yeast (S. cerevisae) 
by a series of alkaline and acidic extraction steps. The yeast cells were collected by 
centrifugation, washed in water, suspended in 1M NaOH, and heated at 90˚C for 1 h. 
The centrifugation and alkali extraction were repeated, the particles were then 
suspended in water at pH 4.5, and heated at 75˚C for 1h, followed by washes of the 
particles with water (three times), isopropanol (four times) and acetone (two 
times).  YGPs were then dried and resuspended in 0.9% saline, sonicated, counted 
on a hematocytometer, aliquoted, and dried to obtain 5 mg/ml YGP samples. 
 
2.2  Synthesis of Cationic GPs (PEI-GP, CN-GP) 
GPs (5 mg) were resuspended in 10 mL of water by homogenization. 
Potassium periodate (0.4 mL of a 1 mg/mL solution) was added and the mixture 
stirred in the dark at room temperature for at least six hours. Oxidized GP samples 
were washed three times with water, and used immediately for reductive amination 
synthesis. Cationic polymers (PEIs and CN) and water were added to the oxidized 
GP samples (1 μmol PEI/mg GP), and the particles were resuspended and mixed at 
room temperature overnight. The aminated samples were reduced with sodium 
borohydride (0.1 g), and incubated at room temperature for 48 hours. The reduced 
samples were washed with water.  Tris buffer (5 mL, pH 7.5, 0.05 M) was added, and 
the sample was incubated for 30 minutes. The samples were washed with water, 
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resuspended in 70% ethanol, and stored overnight at −20°C for sterilization, then 
aseptically washed three times with 0.9% saline, resuspended in 0.9% saline.  The  
particles were counted with a hematocytometer, and the particle suspensions were 
diluted to a concentration of 1 × 108 particles/mL and stored at −20°C. 
 
2.3 Loading of HA Flu Peptide/Ova Core Components Inside the GPs 
Solutions of Ova with a concentration of 25 mg/ml and solution of Alexa HA 
Flu peptide with a concentration of 100 µg/ml were prepared. The empty GP 
samples (5mg) were loaded with Alexa HA peptide (4 µl of 25 µg/µl peptide), then 
incubated for 30 min on ice to allow peptide penetration and lyophilized. The 
samples were then treated with water (3 µl water push) and lyophilized. After this 
step, 5 µl of tRNA were added to the samples and they were incubated for 30 min. 
Another step of water push was performed, and the samples were left for vapor 
hydration overnight. Finally 10 µl of octanoic acid were added to the samples to 
enrobe the core inside the GPs. The samples then were washed three times with 
saline, and the fluorescence of the supernatants was measured to assess peptide-
binding % to the GP-protein/tRNA core inside the GPs.  
 
2.4  OTII Peptide-Albumin/tRNA Core Loading and Lipid Enrobement of 
GPs 
Prior to loading inside glucan particles, solutions of BSA were prepared in 
water with a concentration of 25 mg/ml, and a solution of FL-OTII peptide was 
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prepared in water with a concentration of 10 µg/ml. First, 20µl of the FL OTII 
solution was added to 5 mg of empty GP samples. These samples were incubated for 
30 min on ice and lyophilized. The samples were treated with 15 µl water (water 
push), mixed and lyophilized.  Next, 20 µl of the BSA solution was added to the dry 
FL-OTII peptide-loaded GPs and processed as described above. After this step 15 µl 
of tRNA was added, mixed and incubated for 30 min. The samples then were treated 
with 10 µl of octanoic acid and incubated overnight to lipid enrobe the peptide-BSA-
tRNA core inside GPs. Control samples were also set up using peptide solution but 
without adding trapping polymer. In addition a FL-OTII mixture was prepared and 
used as a tracer to estimate OT-II incorporated in GPs. The particles were collected 
through centrifugation, and the fluorescence of the supernatants was measured to 
evaluate % loading efficiency of the peptide.   
 
2.5  Synthesis of GP-CN-SATA cores 
5 mg of SATA was dissolved in 25 µl of DMSO, and 20 µl of SATA in DMSO 
solution were mixed with 80 µl of PBS.  5 µl of SATA/PBS solution were added to 5 
mg GP and CN-GP samples, then they were mixed and incubated for two hours at 
room temperature.  The samples were washed, centrifuged and lyophilized. 
 
2.6  Derivatization of GP-SATA-Surface 
The GP surface can be derivatized with different molecules used as ligands 
for binding specific functional groups. Different cationic polymers such as chitosan 
or PEI have been added to the surface of GPs, establishing electrostatic or covalent 
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payload binding mechanisms. The surface of cationic GPs was derivatized with 
Chitosan-GP (CN-GP) and Polyethyleneimine-GP (PEI-GP) to provide a binding 
group for further derivatizaton with N-Succinimidyl S-Acetylthioacetate (SATA). 
SATA is a sulfhydryl-containing modification reagent that reacts with primary 
amines (-NH2), which are present in the side chain of antibodies and proteins. SATA 
creates protected sulfhydryl groups that are then treated with hydroxylamine to 
yield sulfhydryl groups for conjugation reactions. CN-GP and PEI GP samples were 
available in Dr. Ostroff’s lab.  
 
2.6.1  Synthesis of Surface Derivatized SATA-GPs 
Previously synthesized CN-GPs, PEI-GPs, and unmodified GPs were labeled 
with SATA.  GPs (5 mg samples) were resuspended in 100 µl of PBS and 100 µl of 
SATA in DMSO solution (20 mg in 600 µl DMSO) were added.  The samples were cup 
sonicated, and incubated for two hours at room temperature. The samples were 
centrifuged and washed three times with water. The GPs then were resuspended in 
1 ml water, aliquoted into tubes (40µl), and lyophilized to obtain 0.2 mg SATA 
labeled GP samples.  
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Particles (5mg) µl PBS µl SATA in DMSO 
CN-GP 100 100 
25kPEI-GP 100 100 
GP 100 100 
PLL-GP 100 100 
DAP-GP 100 100 
Table 1: Synthesis of SATA Surface-Derivatized GPs. 
 
2.6.2  Characterization of SATA Modified GPs (Ellman’s Assay) 
To measure the sulfhydryl derivatization of GPs, the Ellman’s assay was used. 
The Ellman’s method for assaying thiols introduced by reaction of SATA with 
cationic GPs is based on the reaction of thiols with the chromogenic DTNB (5,5′-
dithiobis-2-nitrobenzoate) whereby formation of the yellow dianion of 5-thio-2-
nitrobenzoic acid (TNB) is measured.  SATA surface-derivatized GPs (0.2 mg 
samples) were resuspended in 5 µl of deacetylation solution to allow deprotection 
of SATA.  0.5 M hydroxylamine hydrochloride, 25mM EDTA in PBS deacetylation 
solution was prepared by dissolving 0.0439 g hydroxylamine hydrochloride (0.626 
mmol) and 0.0119 tetrasodium salt of EDTA (0.031 mmol) in 1 ml of PBS. The 
samples were sonicated and incubated for two hours. After the incubation period, 
the samples were washed three times with water. Ellman’s Reagent solution was 
prepared by dissolving 4 mg of Ellman’s Reagent in 0.1 M sodium phosphate buffer, 
pH 8.0, containing 1 mM EDTA.  5 µl of Ellman’s Reagent solution were added to the 
deprotected GP samples and incubated for 15 min at room temperature. 195 µl of 
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sodium phosphate buffer were added to the samples, then the samples were 
centrifuged and transferred to a 96-well plate to measure absorbance at 412 nm.  
 
2.6.3  Peptide Binding to SATA modified GPs 
Two peptides containing cysteine residues were used for binding to SATA 
modified GPs.  One peptide containing a fluorescent tag (fluorescein) was used as a 
model compound to optimize the reaction conditions for binding to SATA modified 
GPs.  A second peptide containing an Ova amino acid sequence was used to produce 
samples with biological activity.  
 
2.6.4 f-Cys Peptide  
 f-Cys peptide containing a fluorescent tag (fluorescein) was tested for 
binding to SATA-GPs. Flow cytometry (FACS) analysis and fluorescent microscopy 
were used to evaluate the binding of the peptide to SATA-GPs, while glutathione 
(GSH) and pH assays were used to indirectly measure the peptide binding and 
release from SATA-GPs.  
 
2.6.5 f-Cys peptide Binding 
5 µl of 0.5 M hydroxylamine hydrochloride, 25 mM EDTA in PBS 
deacetylation solution were added to GP samples (0.2 mg) to allow deprotection of 
SATA. The samples were sonicated and incubated for two hours. After the 
incubation period, the samples were washed three times with water and then 
reacted with 6 µl of f-cys peptide (0.5 mM, 0.3 x 10-5 mmol) overnight in the dark.  4 
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µl of PBS were added to bring the volume of the solution to 10 µl. After the 
incubation period, the samples were resuspended in 190 µl of PBS, centrifuged 
(10,000 rpm for 5 minutes) and the supernatants were transferred to a transparent 
96-well plate, leaving the pellet in the centrifuge tube. The fluorescence of the 
unbound peptide was measured. The pellet was washed three times with 1 ml of 
PBS and resuspended in 500 µl.  Particles were counted with a hematocytometer, 
and the particle concentration was adjusted to 1 x 108 particles/ml with PBS. 
Samples were characterized for peptide binding capacity by indirect measurement 
of peptide bound, and released after incubation of samples in glutathione, flow 
cytometry and fluorescence microscopy.  
 
2.6.6 f-Cys Peptide Binding and Release Assay 
50 µl of the synthesized GP samples at 1 x 108 particles/ml concentration 
were added to microfuge tubes. The samples were mixed with 150 µl of 0.15 M 
glutathione solution, and were incubated in dark room overnight. After the 
incubation period, the samples were centrifuged and the supernatants were 
transferred to a 96-well plate. The fluorescence of f-Cys peptide was measured in 
the glutathione fractions to evaluate the % of f-Cys peptide released. Furthermore, 
the GP samples were resuspended in PBS (pH 7), sodium acetate buffer (pH 5), or 
0.2M glycine-HCl buffers to evaluate the release of f-Cys peptide at different pH 
conditions.  
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2.6.7 Flow Cytometry (FACS) 
FACS measurements were obtained with a Becton Dickinson FACSCalibur 
instrument (BD, Franklin Lakes, NJ). A particle count of the GP samples was 
performed to bring the concentration of GPs to 1 x 108/ml for the FACS analysis. An 
unmodified GP sample was used as the negative control, while fluorescently labeled 
GPs were used as the positive control. The particles were analyzed with a FL4 laser 
at 605 nm by collecting an average of 15000 measurements.  
 
2.6.8 Microscopy 
The synthesized GP particles and unmodified GP were transferred to slides and 
examined under a fluorescence microscope at 100x magnification. Furthermore, the 
f-Cys SATA-GPs (1 x 108 particles/ml) were used in cell uptake experiment.  190 µl 
of 0.9% sterile saline and 10 µl of GPs were mixed and delivered to 3T3-D1 and 
DC2.4 phagocytic cells in DMEM + 10% fetal calf serum + 1%penicillin + 
streptomycin + glutamine (250µl).  The cells were plated in 24-well plates 
containing 1 x 107 cells/well.  The samples were transferred to the labeled wells and 
incubated for one hour at 37˚C and 5% CO2. The cells were washed with PBS and 
fixed with 1% formalin. The cells were examined for evidence of GP mediated 
delivery of f-Cys peptide under a fluorescent microscope at 20x. 
 
2.7  NPYS OVA Peptide 
 After the conditions were optimized using f-Cys peptide, NPYS OVA peptide 
was tested to evaluate binding to SATA GPs and to assess the effects of delivering 
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NPYS OVA to cells. NPYS selectively reacts with free thiol groups forming disulfide 
bonds, thus preventing peptide S-S dimers and providing a colored reaction product 
to measure peptide conjugation efficiency. 
 
2.7.1 NPYS peptide Binding 
The deacetylation of SATA-GP, SATA-PEI-GP and SATA-CN-GP-samples was 
performed as indicated in section 2.1.1. The deprotected SATA-GP samples were 
reacted with 5 µl of 2.5 mM NPYS Ova peptide (1.25*10-5 mmol) and were incubated 
overnight. 5 µl of water were added to obtain a total volume of 10 µl.  After the 
incubation period, the samples were resuspended in 190 µl of water, centrifuged 
(10,000 rpm for 5 minutes) and the supernatants were transferred to a transparent 
96-well plate, leaving the pellet in the centrifuge tube. The absorbance of the 
released Py group in the supernatants was read at 312 nm allowing an estimation of 
the amount of peptide bound to SATA. The pellet was then washed three times with 
1 ml of water, and resusupended in 500 µl of water. 
 
2.7.2 Biological Assay-OTII T Cell Proliferation 
Purified T cells (105 cells/well) were incubated with mitomycin C-treated 
BMDCs (106 cells/well) and the indicated stimuli for 4 days in round-bottom 96-
well plates in 200 µl R10 medium. [3H]-thymidine (1 µCi/well; PerkinElmer, Boston, 
MA) was added for the last 24 h of incubation. Each condition was studied in 
triplicate. Cells were collected on filter paper (Wallac, Turku, Finland) using a 
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harvester (Tomtec, Hamden, CT), and [3H]-thymidine incorporation was measured 
with a beta counter (Wallac 1450 Microbeta).  
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RESULTS 
The purpose of this project was to test different strategies for building core 
complexes inside glucan particles (GPs), adding trapping polymers, and derivatizing 
the GP surface with Chitosan or Polyethyleneimine to provide a binding group for 
further derivatizaton with N-Succinimidyl S-Acetylthioacetate (SATA).  The various 
methods were compared for successful loading and release of the loaded peptide. 
1. OT-II Peptide Loading Inside GPs 
The first set of experiments involved testing the loading efficiency and 
capacity for a fluorescently labeled test peptide, OT-II.  OT-II is an ovalbumin (OVA) 
(323-339) peptide consisting of an ISQAVHAAHAEINEAGR amino acid sequence 
which produces a distinct T cell response.  The OT-II peptide was loaded inside the 
GP and coated with tRNA to assess the peptide binding capacity to GPs.  GP OTII 
peptide/tRNA cores were enrobed with octanoic acid (OA) for retention of the 
peptide inside GPs.  After lipid enrobement, the peptide-loading efficiency was 
evaluated by measuring fluorescence (Figure 3).  The results for the OT-II peptide 
coated with tRNA and enrobed with OA showed a 65% binding efficiency (right 
histobar), while samples with no tRNA (left histobar) or lipid enrobement (middle 
histobar) bound 61% and 48% of peptide, respectively.  These results indicate that 
OT-II peptide/tRNA core enrobed with octanoic acid is the most efficient loading 
method.  
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Figure 3: OT-II Peptide Binding Capacity. 
 
2. HA Peptide and Ova Formulations Inside GPs 
2.1 HA Peptide binding assay 
Fluorescently labeled influenza hemagglutinin HA peptide (fl-HA) and 
Ovalbumin (Ova) formulations were loaded inside the GPs and enrobed with 
octanoic acid to evaluate the loading efficiency.  After the loaded GPs were enrobed 
with lipid, the fluorescence of the GPs was measured to evaluate peptide-loading 
capacity (Figure 4).  The lipid-enrobed GPs showed 48% loading efficiency, while 
the GPs with no enrobement resulted in 6% loading.  
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Figure 4: Lipid Enrobement of the HA Peptide Inside GPs. 
 
2.2 Microscopy 
Further assessment of the fl-HA peptide encapsulation inside GPs was 
measured using fluorescent microscopy.  The GP particles were transferred to slides 
and examined using a fluorescent microscope at 100x.  The data (Figure 5) shows 
fluorescent GPs (left panel), confirming that the peptide was entrapped inside the 
lipid-enrobed particles, while the unenrobed GPs (right panel) showed no 
fluorescence.  
 
 
 
 
 
 
 
Figure 5: Fluorescent Microscopic Images of HA Peptide Formulation Inside GPs. 
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3. SATA Inside GP Core 
SATA is a reagent for introducing protected sulfhydryls into different 
molecules such as proteins, peptides, and other amine-containing molecules. 
Sulfhydryl groups are introduced in a protected form to be stored for longer period 
until treated with hydroxylamine to expose the reactive sulfhydryl on SATA-
modified molecules for final conjugation reactions.  SATA contains an N-
hydroxysuccinimide (NHS) ester, which forms a covalent amide bond with primary 
amines.  The SATA was introduced as a part of the GP-Chitosan (GP-CN) core for 
functionalization with f-cys peptide via sulfhydryl linkages. However, no evidence of 
SATA binding to GP-CN core was observed by Ellman’s method (data not shown). 
 
4. SATA Surface-Derivatized GP 
SATA was used to introduce sulfhydryl groups to the surface of cationic GPs 
to be available for immediate reaction with amine groups. The synthesized SATA-
GPs were evaluated for fluorescent peptide binding and release and cell uptake.  
4.1 Ellman’s Assay 
Ellman’s Assay was used to determine the quantity of sulfhydryl groups (SH) 
introduced by reaction of SATA with cationic GPs.  Table 2 summarizes the 
calculated concentrations (mmol SH/mg GP) of sulfhydryl groups present in the 
unmodified and synthesized GPs, which shows that the amount of free thiols 
introduced by SATA is higher in modified GPs, with SATA-PEI-GP yielding the 
highest concentration.  
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Table 2: Concentration of Free SH Groups in the GPs. 
 SATA-GP SATA-PEI-
GP 
SATA-CN-GP SATA-PLL-
GP 
SATA-
DAP-GP 
GP 
Concentration 
(mmol SH/mg 
GP) 
1.14*10-5 0.82*10-3 2.25*10-5 1.55*10--4 1.78*10-5 0 
 
4.2 Cys-Peptide Binding Capacity 
0.5 mM f-Cys peptide was reacted with the synthesized SATA-GP, SATA-CN-
GP and SATA-PEI-GP formulations, and the % peptide binding was measured using a 
binding assay (Figure 6).  The % binding is the ratio of peptide concentration 
obtained from fluorescence emission measurements divided by the input of peptide 
concentration and multiplied by 100. 
[Measured unbound peptide]/[input peptide concentration]*100 =  
% unbound peptide 
100% - % unbound peptide = % bound peptide 
 
 
 
Figure 6: Percent Peptide Binding of the Synthesized SATA-GP, SATA-CN-GP,  
SATA-PEI GP, SATA-PLL-GP and the Unmodified GP. 
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The results indicate that the highest percent peptide binding resulted from the 
SATA-PEI procedure. 
 
4.3 Flow Cytometry (FACS) 
Fluorescence activated cell sorting (FACS) (flow cytometry) was also used to 
measure the level of fluorescent peptide bound to the synthesized GPs. The results 
shown below reveal that peptide is bound to the particles with SATA-derivatized 
surface (Figure 7).  SATA-PEI-GP, SATA-PLL-GP, SATA-CN-GP showed more peptide 
% binding than SATA-GP, while no peptide was bound to the unmodified GP. 
 
 
Figure 7: FACS Results for the SATA-Labeled GPs and the Unmodified GPs. 
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The particles were transferred to slides and examined using a fluorescent 
microscope at 100x (Figure 8).  The results show clear evidence of fluorescent 
peptide binding to the synthesized GPs, while the unmodified GP showed no traces 
of bound peptide.   
 
Figure 8: Fluorescent Microscopy of f-Cys Peptide Binding to the Synthesized  
SATA-GP, SATA-CN-GP, SATA-PEI-GP and the Unmodified GP. 
 
4.4 Binding and Release Assay 
The next phase of the project involved testing the amount of loaded peptide 
released from various GPs.   When testing the release of peptide from the 
SATA-GP SATA-CN-GP 
SATA-PEI-GP GP 
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synthesized SATA-GPs, both SATA-CN-GP and SATA-GP were used.  These 
synthesized GP samples were treated with 0.15 M glutathione solution and glycine 
buffer (pH 3) to quantify the amount of bound peptide released from SATA-GPs 
(Figure 9). The results showed that most of the peptide under these conditions was 
released from all GP samples in 3 h.  
 
Figure 9: Glutathione and 0.2М Glycine-HCl Buffer-Mediated  
Release of Peptide from SATA-GPs Over 48 hours at 37˚C. 
 
4.5 Flow Cytometry  
Flow cytometry measurements were used to determine the difference 
between the samples before and glutathione reactions.  SATA-GP and SATA-CN-GP 
flow cytometry results are shown in Figures 10 and 11, and indicate that the 
samples treated with glutathione (red) are less fluorescent than the originally 
synthesized GPs (blue) indicating peptide release from the GP. 
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Figure 10: FACS Results for SATA-GP Before and After Glutathione Release. 
 
Figure 11: FACS Results for SATA-Chitosan-GP  
Before and After Glutathione Release. 
 
5. 3T3-D1 and DC2.4 Uptake of f-cys Peptide-Labeled GPs 
The GP particles were delivered in vitro to phagocytic 3T3-D1 and DC2.4 cells 
to assay the uptake of fluorescent peptide-SATA GPs.  The cells were incubated with 
the synthesized GPs for 1 to 3 hours at 37˚C under CO2 to allow efficient particle 
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uptake. The cells were fixed and observed under fluorescent microscope at 20x 
magnification (Figures 12 and 13).  The synthesized GPs successfully delivered 
fluorescent peptide into both 3T3-D1 and DC2.4 cells, however only SATA-PEI-GP 
and SATA-CN-GP showed evidence of efficient peptide binding to the GPs.  
 
Figure 12: Uptake of Fluorescent Peptide-Labeled GPs into Phagocytic DC2.4 Cells. 
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Figure 13: Uptake of Fluorescent Peptide-Labeled GPs into Phagocytic 3T3-D1-Cells. 
 
6. NPYS peptide binding 
After the conditions for f-cys peptide binding to GPs were optimized, the 
NPYS-Ova peptide binding to GPs was tested.  The synthesized SATA-PEI-GP, SATA-
CN-GP, and the unmodified GP were labeled with NPYS-Ova peptide, and the percent  
of binding was quantified (Figure 14).  The NYPS molecules cleave upon reaction of 
the peptide with deprotected SATA allowing measurement of the absorbance that 
directly correlates with bound peptide concentration.  The results show that the 
SATA-CN-GP SATA-PEI-GP 
GP 
GP SATA-GP 
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SATA-PEI-GP (red) and SATA-CN-GP (green) samples have significantly higher 
peptide-binding than control GP (blue).  The SATA-CN-GP % binding was 3x higher 
and SATA-PEI-GP was 10x higher than the control GP.  
 
 
Figure 14: The Percent Binding of NPYS-Ova Peptide  
at Different Peptide Concentrations. 
 
7. Biological Assay: OTII T Cell Proliferation 
In order to demonstrate whether NPYS peptide-encapsulated GPs can be 
effectively delivered to T cells, an in vitro [3H]-thymidine T-cell proliferation assay 
was performed (Figure 15).  CD4+ T cells obtained from OT-II mice which recognize 
the OVA peptide were stimulated in vitro with GP - C(Npys)-OVA peptide.  The 
results indicate that polymer surface-derivatized GP-Npys-OVA led to an enhanced 
CD4+ T cell proliferation, compared to Npys-Ova-GPs (~50% difference). These 
results reveal that the Npys peptide was delivered with GPs and was efficiently 
processed and presented by DCs.  
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Figure 15:  NPYS – OTII Peptide T Cell Proliferation. 
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DISCUSSION 
 
In this project, several novel strategies for the delivery of peptides using beta 
glucan particles were evaluated. Glucan particles have been used for macrophage-
targeted delivery of different payload macromolecules including DNA, siRNA, 
insoluble drugs, and nanoparticles (Soto et al., 2011) and are an effective targeted 
vaccine antigen/adjuvant delivery system (Levitz et al., 2010). There is a growing 
interest for extending the applicability of the glucan particles to deliver low 
molecular weight drug molecules.  This project has focused on the delivery of 
peptides to phagocytic/macrophage cell lines as a potential vaccine formulation and 
use in vivo. Different loading strategies of peptide in GPs were tested, included 
synthesizing protein/GP/peptide/tRNA cores (a layer by layer approach), SATA-CN-
GP cores (SATA derivatization inside the GP-CN cores), and surface-derivatized GPs 
(the GP surface is modified with biodegradable polymers).   
Glucan particles have been successfully used to trap protein molecules such 
as Ovalbumin (OVA) and Bovine Serum Albumin (BSA) by forming a protein/tRNA 
nanoparticulate complex. The first approach tested in this project involved the 
formation of peptide/tRNA cores inside the GPs and its lipid enrobement to enhance 
the peptide retention.  A fluorescent OTII peptide and albumin were loaded together 
into the glucan particles and then tRNA was added to form an insoluble polyplex. 
Efficient adsorption of payloads into glucan particles was achieved by soaking dry 
particles in the hydrodynamic volume of the particles. The wet samples were then 
lyophilized before tRNA addition to ensure maximum adsorption of the peptide. 
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Trapping polymer (tRNA) was then added to form the stable complex within the 
particles.  The final compound added to this formulation is octanoic acid to enrobe 
or coat the payload core within the GPs to enhance the peptide retention capacity. 
The amount of OTII peptide bound to the particles was indirectly measured by 
measuring the amount of unbound fl-peptide. Three different loading strategies 
were evaluated for % OTII peptide binding: tRNA complexation and a lipid 
enrobement slightly increased the % peptide binding. The results in Figure 3 
demonstrate efficient binding of the peptide. Formulations of both tRNA and 
octanoic acid contain 65% of peptide, while samples missing one of these 
components bound less peptide. In addition to binding assay the samples were 
evaluated under fluorescent microscope to confirm % peptide binding. These 
results confirmed the binding of the peptide and its retention inside the cores. 
As another example of GP peptide core loading, a fluorescent Alexa HA 
peptide/Ova/tRNA complex was synthesized inside the GPs. In this method, 
lyophilization steps were carried out to maximize the adsorption of each core 
component and the core inside GP was enrobed with octanoic acid to increase 
retention capacity. The control sample prepared without tRNA and octanoic acid 
showed 6% binding, while trapping as a protein complex yielded 48% binding 
(Figure 4). Moreover, the samples were observed under fluorescent microscope at 
100x to confirm peptide presence inside the GPs. Figure 5 clearly shows the 
fluorescence of the Alexa HA peptide/Ova sample, while no fluorescence traces were 
observed in the control sample. The combination of trapping polymers tRNA and 
octanoic acid ensured efficient retention of the payload inside the core.  
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However, there is a limit to the amount of peptide that can be encapsulated 
inside GPs as a polyplexed core. To overcome this limitation, an alternative method 
of encapsulating payload was devised.  Formulation of chitosan (CN)/SATA/GP 
cores and its functionalization with f-Cys peptide via sulfhydryl linkages was tested. 
Due to the similarity between biologically active NYPS peptide and f-Cys peptide, the 
latter was used to optimize conditions for GP loading. The results obtained from 
CN/SATA/GP core functionalization did not show any evidence of SATA binding to 
GP-CN core. One of the possible reasons why SATA did not bind GP-CN core might be 
due to the small volume of the GP, which resulted in no reaction or that insoluble 
chitosan was not available for reaction with SATA. 
We next designed a new peptide GP surface binding strategy. Surface 
derivatization methods, such as reductive amination and click chemistry, allow for 
many different molecules and polymers to be added to the GP surface. Due to 
inefficient binding of peptide to cores inside the hollow cavity of GPs the surface of 
GP were derivatized with cationic polymers and SATA to introduce sulfhydryl 
groups to the surface of GPs for further peptide conjugation reactions. First, cationic 
polymers such as PEI were added to the surface of GP, creating a payload binding 
mechanism. Once the functional groups were added to the surface, the GP samples 
were derivatized with SATA to form free sulfhydryl functional groups.  The available 
primary amine on the peptide reacted with the introduced NHS ester to form a 
stable, covalent amide by nucleophilic attack.  The free sulfhydryls (SH) were 
formed following the hydroxylamine-mediated deprotection step and quantified 
using Ellman’s Assay. The results presented in Table 1 show the concentration of 
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quantified free SH groups in the synthesized GP samples.  The SATA-PEI-GP yielded 
the highest number of free SH groups, while the remaining samples showed less free 
thiols available for reaction with peptide. After the amount of free SH groups in the 
samples was quantified, the samples were reacted with f-cys peptide, and the 
binding capacity of the GPs were measured indirectly. The measurements shown in 
Figure 6 reveal that the SATA-PEI derivatized samples were effective in binding 
90% of the peptide, while unmodified GP bound only 10%.  The SATA-GP sample 
showed only 13% binding, revealing that a cationic polymer enhances peptide 
binding to the GPs.  A fluorescence activated cell sorter (FACS) assay (flow 
cytometry) was also used to confirm binding of fluorescent peptide to the 
synthesized SATA-GPs and unmodified GP.  The results showed that unmodified GPs 
do not bind the f-cys peptide but binds to SATA derivatized GPs (Figure 7). The 
particles that showed clear evidence of binding were transferred to slides and 
examined under fluorescent microscope at 100x. The obtained microscopy images 
confirmed the binding assay and FACS analysis results; Figure 8 shows efficient f-cys 
peptide binding to SATA-PEI-GP, SATA-GP, and SATA-CN-GP, while unmodified GP 
showed minimal or no binding. The synthesized GPs were evaluated for peptide-
binding-release stability at pH 5 and pH 7. F-cys peptide release from the 
synthesized SATA-CN-GP and SATA-GP samples was mediated by both glutathione 
solution (GSH, pH 7) and glycine-HCl buffer (pH 3) at 37˚C, and the % released 
peptide was measured over 48 hour period (Figure 9). It was hypothesized that 
glutathione will facilitate the release of the peptide by cleaving the disulfide bonds 
between peptide and thiols, while glycine buffer of low pH will inhibit thiol-disulfide 
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interchange reactions (McKenzie et al., 1972). The observed results yielded ~50% 
peptide released from the samples after 48 h GSH incubation. Although the peptide 
is cleaved from SATA in the presence of GSH, it is possible that some of it remains 
non-covalently bound to the chitosan through charge interactions. A flow cytometry 
assay was used to confirm the release of peptide after GSH treatment. Figures 10 
and 11 show a difference between SATA-GP and SATA-CN-GP samples before and 
after GSH, corroborating the results from the release assay.  
At low pH, CN should not be able to bind peptide, and the percent released 
should be higher. However, the data from the experiment did not show any 
significant difference in % peptide release over time in low pH solution. This might 
have been due to at least 2x larger binding capacity of SATA-CN-GP than that of 
SATA-GP, which results in more peptide needed for cleavage from SATA-CN-GP.  
Next, the synthesized samples were evaluated for cellular uptake of 
fluorescent peptide using the phagocytic NIH3T3-D1 and DC2.4 dendritic cell line 
expressing glucan receptors.  The cells were incubated loaded with synthesized GPs 
for 1, 3, and 24 hours, and observed under fluorescent microscope at 20x. The GP 
surface-modified samples loaded in these cell lines showed clear fluorescence after 
1h and 3h incubation periods. However, no evidence of fluorescent particles was 
observed after 24 hr incubation.  A possible reason for this may be a complete 
cleavage of the f-cys peptide from the particles over 24 h time period followed by 
peptide degradation. Microscopic evaluation of the synthesized samples shows 
efficient peptide binding and uptake of SATA-PEI-GP and SATA-CN-GPs by both cell 
lines.  The SATA-GP sample showed less % binding and thus less efficient uptake by 
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the cells, while the unmodified GP sample resulted in no cell uptake. These particle 
uptake experiments confirmed the stability results (Figure 12 and 13), the PEI 
surface modification of GPs or the binding of f-cys peptide to the SATA-PEI-GPs had 
no negative impact on cellular toxicity. The results from these studies of f-cys 
peptide binding allowed for optimization of conditions to test the NYPS-Ova peptide 
for binding to the GPs and its biological activity. Samples were reacted with varying 
concentrations of NPYS-Ova peptide to assess binding capacity. Lower 
concentrations of NYPS peptide (0.5 mM) showed 50% binding to the SATA-PEI-GP 
sample, while no binding to SATA-CN-GP and unmodified GP was observed. An 
increased concentration of the peptide (2.5 mM) significantly enhanced peptide 
binding to SATA-PEI-GP (73%) and SATA-CN-GP (16%). Finally, peptide of doubled 
concentration (5 mM) was reacted with samples, yielding 56% and 61% binding to 
SATA-PEI-GP and SATA-CN-GP, respectively.  The unmodified GP bound 18% 
peptide due to the higher concentration of the peptide reacted (Figure 14). The use 
of derivatized surface GPs allows efficient peptide binding compared to the 
unmodified GPs, demonstrating the visible effects or toxicity on the dendritic cells.  
Since our final aim was to develop a vaccine formulation of Npys-OVA-
peptide loaded GPs, we evaluated the effect of these formulations to induce 
presentation by dendritic cells to T-cells in an in vitro setting.  The Npys-Ova-
peptide was loaded in surface-modified GPs, as well as f-Cys peptide. The activity of 
these formulations was evaluated by a [3H]-thymidine T-cell proliferation assay. 
Different Npys-Ova and f-Cys peptide-modified GP samples were cultured with 
CD4+ OT-II cells, and the proliferation of T cells was assessed by [3H]-thymidine 
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incorporation.  As seen on Figure 15, Npys-OVA-loaded surface-derivatized GPs led 
to improved CD4+ T cell proliferation, compared to Npys-OVA-GPs, while f-Cys 
peptide GPs did not generate any biological response, which was proved by lack of 
signal in these samples.  SATA-GP was also tested to confirm that the response 
resulted from the NPYS-OVA peptide. The results presented show that the Npys-
OVA-peptide encapusulated in surface modified GPs significantly enhances OVA-
specific T cell proliferation in vitro.  
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CONCLUSIONS AND FUTURE WORK 
 
In this project, three strategies for a targeted delivery of peptides with glucan 
particles (GPs) were tested. Synthesizing cores inside GPs using a layer-by-layer 
approach, SATA derivatization inside GP-CN-cores, and SATA and polymer 
derivatization of the GP surface were evaluated revealing that surface-derivatized 
GPs enhances the delivery of the OVA-peptide to the cells and is biologically active. 
The Npys peptide bound to the surface-derivatized GPs with a binding efficiency 
greater than 60%, and stimulated a strong T cell proliferation in vitro.  In the future, 
the next step will be to test the Npys-OVA-GP formulation in vivo in mice, as well as 
finding an alternative biodegradable polymer with minimal toxicity effects on cells. 
Additionally, new formulations that may provide higher drug binding capacity and 
controlled release need to be studied.  
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